Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this
conference was to develop an expert consensus-driven working framework for …

Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Background BRCA1 and BRCA2 mutations have been associated with prostate cancer
(PCa) risk but a wide range of risk estimates have been reported that are based on …

Background Germline mutations in BRCA1/2 and ATM have been associated with prostate
cancer (PCa) risk. Objective To directly assess whether germline mutations in these three …

BACKGROUND Breast cancer 2 (BRCA2)‐associated breast and ovarian cancers are
sensitive to platinum‐based chemotherapy. It is unknown whether BRCA2‐associated …

Germline mutations in the BRCA2 tumour suppressor are associated with both an increased
lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease …

Background A prior meta‐analysis found no association between BRCA1 mutation and
prostate cancer (PCa). Subsequent BRCA2 mutation studies have shown an association …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

Beyond breast and ovarian cancers, mutations in the BRCA1 and BRCA2 genes increase
risks for pancreatic and prostate cancers and contribute to the prevalence of these cancers …